Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

This study will assess safety, tolerability, and effect of LIK066 on blood glucose in healthy subjects and in patients with T2DM.

Phase 1/Phase 2

Novartis Pharmaceuticals

Licogliflozin